• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

856676-23-8 (Choline Fenofibrate)

1

Identification

Choline Fenofibrate Choline Fenofibrate
Name Choline Fenofibrate
Formula C22H28ClNO5
MW 421.91
CAS No. 856676-23-8
EINECS
Smiles O=C(C1=CC=C(OC(C)(C([O-])=O)C)C=C1)C2=CC=C(Cl)C=C2.C[N+](C)(CCO)C
Synonyms ABT-335;ABT 335;ABT335; 2-hydroxy-N,N,N-trimethylethanaminium 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
InChI InChI=1S/C17H15ClO4.C5H14NO/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11;1-6(2,3)4-5-7/h3-10H,1-2H3,(H,20,21);7H,4-5H2,1-3H3/q;+1/p-1
2

Introduction

Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia.

Background Information

Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. IC50 value: Target: Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia. ......by MedChemexpress Co., Ltd.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:Light yellow to yellow Solid EBNumber:EB000023019

Storage condition

Solubility

DMSO by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Choline Fenofibrate University of Utah Lipid metabolism disorder 2009/11/30 2011/11/30 Phase 4 Clinical
Choline Fenofibrate Piedmont Hospital Coronary atherosclerosis 2009/11/30 2010/11/30 Phase 3 Clinical
Choline Fenofibrate Abbott Laboratories Coronary artery disease 2008/6/30 2011/4/30 Phase 3 Clinical
Choline Fenofibrate Abbott Laboratories Lipid metabolism disorder 2008/2/29 Phase 3 Clinical
Choline Fenofibrate AbbVie Inc Lipid metabolism disorder 2008/2/29 2012/9/1 Phase 3 Clinical
Choline Fenofibrate - Launched
Choline Fenofibrate - Phase 3
7

Safety Data of Choline Fenofibrate

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
CHEMSCENE, LLC USA
Carbosynth Limited 500mg/USD70()
Clearsynth Labs Limited 25mg/USD250() India
MedChemexpress Co., Ltd. 10mg/USD100(In stock);100mg/USD820(In stock) USA
Santa Cruz Biotechnology, Inc. 10mg/USD240() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 10mg/USD110(Get quote);100mg/USD880(Get quote) China
Toronto Research Chemicals Inc. 1mg/USD65() Canada
Zhejiang Excel Pharmaceutical Co., Ltd. China
10

Related Products

Other Forms of 856676-23-8

Name CAS No Formula MW

Recommended Compounds in PPAR Cytochrome P450

Name CAS No Formula MW
(20S)-Protopanaxatriol 34080-08-5 C30H52O4 476.73
Procyanidin B2 29106-49-8 C30H26O12 578.52
Eupatilin 22368-21-4 C18H16O7 344.32
Fenofibric acid 42017-89-0 C17H15ClO4 318.75
Ciprofibrate 52214-84-3 C13H14Cl2O3 289.15
Bezafibrate 41859-67-0 C19H20ClNO4 361.82
Clofibrate 637-07-0 C12H15ClO3 242.7
Gemfibrozil 25812-30-0 C15H22O3 250.33
Pioglitazone 111025-46-8 C19H20N2O3S 356.44
Acetic acid, 2-[4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]- 317318-84-6 C21H17F4NO3S2 471.49
CDDO-Im 443104-02-7 C34H43N3O3 541.72
FH535 108409-83-2 C13H10Cl2N2O4S 361.2
Inolitazone (dihydrochloride) 223132-38-5 C27H28Cl2N4O4S 575.51
GW1929 196808-24-9 C30H29N3O4 495.57
Magnolol 528-43-8 C18H18O2 266.33
Naringenin 480-41-1 C15H12O5 272.25
GSK3787 188591-46-0 C15H12ClF3N2O3S 392.78
Daidzein 486-66-8 C15H10O4 254.24
GW9662 22978-25-2 C13H9ClN2O3 276.68
Rosiglitazone 122320-73-4 C18H19N3O3S 357.43

Recommended Compounds in Same Indication

Name CAS No Formula MW
Anacetrapib 875446-37-0 C30H25F10NO3 637.51
Laropiprant 571170-77-9 C21H19ClFNO4S 435.9
Varespladib 172732-68-2 C21H20N2O5 380.39
Ticagrelor 274693-27-5 C23H28F2N6O4S 522.57
Darapladib 356057-34-6 C36H38F4N4O2S 666.77
Genistein 446-72-0 C15H10O5 270.24
Rimonabant 168273-06-1 C22H21Cl3N4O 463.79
Tirofiban (hydrochloride monohydrate) 150915-40-5 C22H39ClN2O6S 495.07
Otamixaban 193153-04-7 C25H26N4O4 446.5
Fenofibrate 49562-28-9 C20H21ClO4 360.83
DAPT 208255-80-5 C23H26F2N2O4 432.46
Ezetimibe 163222-33-1 C24H21F2NO3 409.43
Dalcetrapib 211513-37-0 C23H35NO2S 389.59
Fasudil (Hydrochloride) 105628-07-7 C14H18ClN3O2S 327.83
Evacetrapib 1186486-62-3 C31H36F6N6O2 638.65
Rimonabant (Hydrochloride) 158681-13-1 C22H22Cl4N4O 500.25
Everolimus 159351-69-6 C53H83NO14 958.22
Febuxostat 144060-53-7 C16H16N2O3S 316.37
Prasugrel 150322-43-3 C20H20FNO3S 373.44
RVX-208 1044870-39-4 C20H22N2O5 370.4
11

Route of Synthesis

12

References

13

More Information

Choline Fenofibrate

Tags: buy 856676-23-8 IC50 | 856676-23-8 price | 856676-23-8 cost | 856676-23-8 solubility | 856676-23-8 purchase | 856676-23-8 manufacturer | 856676-23-8 research buy | 856676-23-8 order | 856676-23-8 MSDS | 856676-23-8 chemical structure | 856676-23-8 Storage condition | 856676-23-8 molecular weight | 856676-23-8 mw | 856676-23-8 datasheet | 856676-23-8 supplier | 856676-23-8 cell line | 856676-23-8 NMR | 856676-23-8 MS | 856676-23-8 IR | 856676-23-8 solubility | 856676-23-8 Safe information | 856676-23-8 Qc and Spectral Information | 856676-23-8 Clinical Information | 856676-23-8 Clinical Trial | 856676-23-8 Route of Synthesis | 856676-23-8 storage condition | 856676-23-8 diseases and conditions | 856676-23-8 flash point | 856676-23-8 boiling point | 856676-23-8 melting point | 856676-23-8 storage condition | 856676-23-8 brand